Chlorothiazide

CHEMBL842 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
295.7 g/mol
LogP
-0.2
Phase
4

The first thiazide diuretic developed, working by inhibiting sodium and chloride reabsorption in the distal tubule of the kidney to promote urine output and lower blood pressure. It is used to treat hypertension and edema associated with heart failure, renal disease, and cirrhosis. Metabolic side effects include hypokalemia, hyperglycemia, and elevated uric acid levels.

Peso Molecular

295,7000 g/mol

LogP

-0,20

TPSA

135,00 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Mecanismo de Ação

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O

InChI

InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)

Molecular Formula

C7H6ClN3O4S2

HBD / HBA

2 / 6

Ligações Rotacionáveis

1

Átomos Pesados

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

The first thiazide diuretic developed, working by inhibiting sodium and chloride reabsorption in the distal tubule of the kidney to promote urine output and lower blood pressure. It is used to treat hypertension and edema associated with heart failure, renal disease, and cirrhosis. Metabolic side effects include hypokalemia, hyperglycemia, and elevated uric acid levels.

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Yes, Chlorothiazide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL842. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2720. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.